Cáncer de la Vejiga

What is the Bladder? The bladder serves as a reservoir for urine in our bodies. It permits the storage of urine for a period of time before releasing it as we urinate. It can be thought of as a muscular balloon; it is a flat structure when there is no urine (immediately after a person urinates), but is able to fill up to a liter or so of urine when needed (though this would be very uncomfortable). Normally, as the bladder nears 500 cc (1/2 of a liter), we feel the urge to urinate. The muscular structure of the bladder also helps other pelvic muscles push the urine out when it is released. The bladder is located deep in the pelvis, just above the pubic symphysis, which is a bone that can be felt in the midline on the front of the pelvis. In fact, when the bladder is over distended, it can be felt by a physician. Ureters empty urine into the bladder from the kidneys, and the urethra leads ... read more on Bladder Cancer: The Basics

Frequently Asked Questions

Expert answers to common questions about bladder cancer.

BCG Treatment for Bladder Cancer and Hepatitis
Dear OncoLink "Ask the Experts," I was diagnosed with bladder cancer in 1990, and had two transuretheral removals of tumors. After the second recurrence I received BCG treatment and had good results. This year I was diagnosed with Hepatitis C. A friend of mine, who is receiving the BCG treatment directed me to OncoLink Web site where

BCG Treatment for Bladder Cancer
Dear OncoLink "Ask the Experts," I am presently being treated with a drug named BCG for bladder cancer. The drug is placed into the bladder once a week for six weeks. The instructions make the material seem contaminating. Why does this material need to be treated so carefully? Thank you, TF John Han-Chih

BCG for Bladder Tumors in Dogs
Dear OncoLink "Ask The Experts," Do you have any information on using BCG to reduce the size of bladder tumors in dogs? Lili Duda, VMD, Section Editor of the OncoLink Veterinary Oncology Menu, responds:BCG, or bacillus Calmette-Guerin is a bacterial vaccine that is a non-specific immunomodulator--in other words, it generally stimulates the

Bladder Cancer News

News related to the diagnosis, treatment and side effect management in bladder cancer.

"Never Events" Rare After Bladder Cancer Surgery
Apr 5, 2013 - "Never events", ten hospital-acquired conditions deemed by the Centers for Medicare and Medicaid Services as being reasonably preventable, are rare in patients with bladder cancer who have undergone radical cystectomy, according to a study published in the March issue of Urology.

Gene Variants in RGS Linked to Bladder Cancer Outcomes
Mar 26, 2013 - For patients with bladder cancer, genetic variants in the regulator of G-protein signaling pathway are associated with risk, recurrence, progression, and death, according to a study published online March 25 in Cancer.

Low-Risk Bladder Cancer Rarely Progresses to Muscle Invasion
Mar 6, 2013 - Low-risk bladder cancer rarely progresses to muscle invasion but is associated with an increased risk of disease-specific mortality compared with matched populations, according to research published in the March issue of The Journal of Urology.

Conference Coverage

Reviews of presentations at professional meetings related to bladder cancer.

SWOG 8710 (INT-0080): Randomized Phase III Trial of Neoadjuvant MVAC+Cystectomy Versus Cystectomy Alone in Patients With Locally Advanced Bladder Cancer
Presenter: R.B. Natale Affiliation: SWOG Background: Radical cystectomy has been the gold standard for the treatment of locally advanced bladder cancer. However, 50-60% develop recurrent or metastatic disease after cystectomy. It has been hypothesized that neoadjuvant therapy for advanced bladder cancer will 1)immediately treat

Selective Bladder Preservation by Combined Modality Treatment of Invasive Bladder Cancer: 10 Year Outcome
Presenter: W. U. Shipley Affiliation: Massachusetts General Hospital BackgroundThe standard of care for muscle invasive bladder cancer is radical cystectomy +/- adjuvant chemotherapy with or without radiation. However, to improve quality of life in these patients, there is much interest in bladder-conserving therapies, using transurethral

p21 and p53 as prognostic factors for bladder preservation and survival in patients with bladder cancer treated with neoadjuvant chemotherapy
Presenter: Garcia Del MuroPresenter's Affiliation: Institut Catala d'Oncologia-Ciutat Sanitaria de BellvitgeType of Session: ScientificBackground Muscle invasive cancer has traditionally been treated with cystectomy. However, more recently, combined chemoradiation has been used as a bladder sparing regimen in selected patients. This study